What New Medical Cannabis Patients Say After One Month: Most Report It Helps Their Chronic Pain | Research

The takeaway

After one month of medical cannabis use, 63% of chronic pain patients reported it was effective overall — many also reduced their use of prescription pain and psychiatric medications.

Read this if you're considering medical cannabis for chronic pain — these first-hand experiences of what works, what doesn't, and what to expect are more practical than most clinical studies.

What the researchers found

Patient experience data is often overlooked in cannabis research, where the focus tends to be on controlled trials. This pilot study did something simple but valuable: interviewed 51 adults who were newly starting medical cannabis for chronic pain and asked them how it was going after about one month.

The majority (62.7%) reported medical cannabis was overall effective. The benefits went beyond just pain reduction. Patients commonly reported reduced pain intensity as expected, but also decreased anxiety, improved physical functioning, better sleep quality, and improved mood. Perhaps most notably, many reported reducing their use of both pain medications and psychiatric medications.

The challenges patients reported were equally informative. Finding the right product, dose, and route of administration was the most common difficulty. Many described a trial-and-error process with minimal guidance from either their certifying physician or the dispensary staff. Cost was another barrier — medical cannabis is not covered by insurance, and some patients found the ongoing expense unsustainable.

Some patients experienced side effects including excessive sedation, dry mouth, and cognitive effects. A few reported the cannabis wasn't effective at all for their pain. The interviews revealed a complex picture: medical cannabis helped most patients, but the path to finding the right approach was often frustrating and poorly supported.

Why it matters

Controlled trials tell us whether a drug works on average; patient-reported outcomes tell us whether it works in practice. For medical cannabis — where products, doses, and routes of administration vary enormously — the patient experience is especially important. This study captures the messy reality of being a new medical cannabis patient: the hope, the frustration of finding the right product, and the gap between getting a cannabis card and getting effective treatment.

The numbers in context

51 participants interviewed. 62.7% reported overall effectiveness. Mean age 54.4 years (SD 12.0). 24 women, 27 men. Commonly reported benefits: reduced pain intensity, decreased anxiety, reduced medication use, improved physical functioning, better sleep, improved mood. Common challenges: finding the right product/dose, cost, side effects.

How the study worked

Qualitative analysis of interview data from 51 adults newly initiating medical cannabis for chronic pain, conducted approximately one month after starting use. Participants were part of a three-month pilot study. Demographics: 24 women, 27 men, mean age 54.4, majority Non-Hispanic White (n=41). Responses analyzed using the RADaR (Rigorous and Accelerated Data Reduction) technique.

Who was studied

N=51 adults aged 40-75, 47% female, initiating medical cannabis for chronic pain.

What this study cannot tell us

Small pilot study with only 51 participants, predominantly White, from one geographic area. One-month follow-up is very early — perceived effectiveness may change over time (tolerance could reduce benefits, or patients might find better products). Self-selected sample — people who stayed in the study may differ from those who dropped out. Interview data captures perceptions, not objective outcomes. No placebo comparison — some of the reported benefit may reflect placebo response or expectation effects.

How to read the evidence

This is a small, uncontrolled pilot study using qualitative interview data. It captures the patient experience well but cannot establish whether medical cannabis is more effective than placebo for chronic pain. The findings are exploratory.

When this study was published

Published in 2023. Medical cannabis access, product availability, and clinician training continue to evolve.

The bigger picture

This pairs with the geriatric sleep study (RTHC-00095) and the gynecological pain study (RTHC-00102) in showing how real patients navigate medical cannabis. The common thread across all three: patients are largely on their own in figuring out what works, clinician guidance is minimal, and the trial-and-error process can be frustrating even when the outcome is positive.

Replication

Not stated in abstract.

Funding

Not reported in abstract.

Conflicts of interest

Not reported in abstract.

Questions still open

Does perceived effectiveness persist at 3, 6, and 12 months? Do patients who reported reducing prescription medications maintain those reductions long-term? Would structured dosing guidance (from a pharmacist or cannabis-trained clinician) improve outcomes compared to the current trial-and-error approach? What distinguishes patients who found cannabis effective from those who didn't?

Read the original research

Perceived Effectiveness of Medical Cannabis Among Adults with Chronic Pain: Findings from Interview Data in a Three-Month Pilot Study.

Cannabis (Albuquerque, N.M.), 6(2), 62-75

Cannabis is a peer-reviewed journal focusing on research related to cannabis and its medical applications.

View on PubMed ↗Publisher’s paper ↗

Citation

McMahon, Alexandra N; Varma, Deepthi S; Fechtel, Hannah; Sibille, Kimberly; Li, Zhigang; Cook, Robert L; Wang, Yan. (2023). Perceived Effectiveness of Medical Cannabis Among Adults with Chronic Pain: Findings from Interview Data in a Three-Month Pilot Study.. Cannabis (Albuquerque, N.M.), 6(2), 62-75. https://doi.org/10.26828/cannabis/2023/000149